Algert Global LLC Sells 20,990 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Algert Global LLC lowered its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 31.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 45,350 shares of the biopharmaceutical company’s stock after selling 20,990 shares during the period. Algert Global LLC’s holdings in Intra-Cellular Therapies were worth $3,318,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the business. Oak Ridge Investments LLC acquired a new stake in Intra-Cellular Therapies in the second quarter valued at approximately $811,000. SG Americas Securities LLC boosted its stake in shares of Intra-Cellular Therapies by 962.7% in the 2nd quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock valued at $3,341,000 after purchasing an additional 44,188 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Intra-Cellular Therapies by 6.5% during the third quarter. TimesSquare Capital Management LLC now owns 438,083 shares of the biopharmaceutical company’s stock worth $32,055,000 after buying an additional 26,600 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in Intra-Cellular Therapies in the second quarter valued at $14,755,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Intra-Cellular Therapies by 31.9% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock valued at $33,258,000 after buying an additional 109,892 shares during the period. Institutional investors own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ITCI shares. JPMorgan Chase & Co. upped their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Morgan Stanley boosted their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Needham & Company LLC restated a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. UBS Group dropped their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Royal Bank of Canada raised their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $97.23.

Intra-Cellular Therapies Stock Down 0.8 %

Shares of NASDAQ:ITCI opened at $84.99 on Tuesday. Intra-Cellular Therapies, Inc. has a 12-month low of $58.14 and a 12-month high of $93.45. The stock has a market cap of $9.01 billion, a price-to-earnings ratio of -97.69 and a beta of 0.97. The business’s 50 day moving average is $79.25 and its 200 day moving average is $74.84.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Intra-Cellular Therapies’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) EPS. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sharon Mates sold 34,396 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. The trade was a 3.11 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.